Overview

S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by monoclonal antibody therapy in treating patients who have newly diagnosed follicular non-Hodgkin's lymphoma.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Southwest Oncology Group
Collaborator:
National Cancer Institute (NCI)
Treatments:
Antibodies
Antibodies, Monoclonal
Cyclophosphamide
Doxorubicin
Iodine
Iodine-131 anti-B1 antibody
Liposomal doxorubicin
Prednisone
Tositumomab I-131
Vincristine
Criteria
DISEASE CHARACTERISTICS: Histologically confirmed follicular non-Hodgkin's lymphoma No
prior treatment Bulky stage II, stage III, or stage IV Must express cluster of
differentiation antigen 20 (CD20) antigen Bidimensionally measurable disease No Central
Nervous System (CNS) involvement

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy: Not
specified Hematopoietic: Granulocyte count at least 1500/mm3 Platelet count at least
100,000/mm3 Hepatic: Not specified Renal: Not specified Cardiovascular: No arrhythmias
(except sinus arrhythmia or infrequent premature ventricular contractions) No history of
impaired cardiac status (severe coronary artery disease, cardiomyopathy, congestive heart
failure, or serious arrhythmia Ejection fraction at least normal Other: HIV negative No
prior malignancy within past 5 years except adequately treated basal cell or squamous cell
skin cancer or carcinoma in situ of the cervix No pregnant or nursing Fertile patients must
use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: No prior monoclonal antibodies Chemotherapy: No
prior chemotherapy for lymphoma Endocrine therapy: Not specified Radiotherapy: No prior
radiotherapy for lymphoma Surgery: Not specified